Amarin Corporation plc - American Depositary Shares (AMRN) Covered Calls
Amarin Corporation plc is a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company’s primary product is VASCEPA, a prescription-only omega-3 fatty acid product derived from fish oil. Amarin operates globally, providing treatments designed to reduce cardiovascular risk in patients with elevated triglyceride levels and established cardiovascular disease or diabetes with other risk factors.
You can sell covered calls on Amarin Corporation plc - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AMRN (prices last updated Tue 4:16 PM ET):
| Amarin Corporation plc - American Depositary Shares (AMRN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 14.55 | +0.04 | 14.25 | 15.59 | 28K | - | 0.0 |
| Covered Calls For Amarin Corporation plc - American Depositary Shares (AMRN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 15 | 0.05 | 15.54 | -3.5% | -319.4% | |
| May 15 | 15 | 0.00 | 15.59 | -3.8% | -43.3% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Amarin Corporation plc (AMRN) is dedicated to the innovative treatment of cardiovascular disease. The company’s lead product, VASCEPA (icosapent ethyl), is a high-purity prescription form of eicosapentaenoic acid (EPA). Unlike standard fish oil supplements, VASCEPA has been clinically proven to reduce the risk of major adverse cardiovascular events, such as heart attacks and strokes, in high-risk patients. The company generates revenue through direct sales in the United States and various international partnerships in Europe, China, and the Middle East.
The company’s business model centers on the "REDUCE-IT" cardiovascular outcomes study, which provided the clinical foundation for VASCEPA’s expanded labels. Amarin continues to invest in market access and professional education to increase the adoption of EPA therapy within the medical community. While the firm faces generic competition in certain markets, it maintains a strong focus on defending its intellectual property and expanding the geographic reach of its branded product through its integrated global supply chain and manufacturing partnerships.
Competitive Landscape
The cardiovascular pharmaceutical market is highly competitive, featuring large-cap pharmaceutical giants and specialized biotechnology firms. Amarin competes on the basis of clinical evidence, payer coverage, and patient affordability. Key competitors include:
- Pfizer Inc.: A global biopharmaceutical leader that offers a broad range of cardiovascular treatments and competes for patient market share in the lipid-management space.
- Novartis AG: A major pharmaceutical company with a significant cardiovascular portfolio, including advanced therapies for heart failure and high cholesterol.
- Amgen Inc.: A biotechnology giant that produces high-end PCSK9 inhibitors and other cardiovascular treatments targeting high-risk patient populations.
- AstraZeneca PLC: A global pharmaceutical firm with a strong presence in the metabolic and cardiovascular sectors, offering various treatments for chronic heart and kidney diseases.
Strategic Outlook and Innovation
The company is focused on a long-term strategy of "Global Commercial Expansion and Lifecycle Management." Strategic innovation efforts are directed toward the development of new fixed-dose combinations and the exploration of EPA’s potential in treating other inflammatory and metabolic conditions. By expanding the clinical applications of its core technology, the firm aims to offset the impact of generic entrants and stabilize its long-term revenue streams in the highly regulated global healthcare market.
Increasing penetration in the European market through its brand, VAZKEPA, remains a central pillar of the firm’s growth plan. The company is also leveraging digital health platforms to improve patient adherence and streamline the prescribing process for healthcare providers. Furthermore, the firm continues to optimize its cost structure to maintain financial flexibility during its transition from a single-market focused firm to a global commercial entity. This commitment to cardiovascular innovation and strategic geographic growth is designed to secure the company’s position as a leader in heart health management.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TSLA covered calls | 1. | CMPX covered calls | |
| 2. | SLV covered calls | 7. | KWEB covered calls | 2. | VISN covered calls | |
| 3. | EEM covered calls | 8. | TLT covered calls | 3. | CAR covered calls | |
| 4. | SPY covered calls | 9. | SOFI covered calls | 4. | LWLG covered calls | |
| 5. | QQQ covered calls | 10. | HYG covered calls | 5. | AXTI covered calls | |
Want more examples? AMRC Covered Calls | AMRX Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
